Health Catalyst insider notice: 8,335 shares proposed for sale on 09/02/2025
Rhea-AI Filing Summary
Health Catalyst, Inc. (HCAT) Form 144 shows a proposed sale of 8,335 shares of common stock through Morgan Stanley Smith Barney on 09/02/2025 on the NASDAQ, with an aggregate market value of $28,028.10. The filing reports the shares were acquired the same day (09/02/2025) as restricted stock from Health Catalyst as compensation. The filer previously sold 8,658 restricted shares on 06/02/2025 for gross proceeds of $31,470.10. The total number of outstanding shares is listed as 70,373,625. By signing, the seller represents no undisclosed material adverse information about the issuer.
Positive
- Proper disclosure: The filer formally reports the proposed sale and past sale as required under Rule 144
- Transaction details provided: Broker, dates, share counts, gross proceeds and acquisition nature are all disclosed
Negative
- Same-day acquisition and proposed sale: The 8,335 shares were acquired as restricted stock on 09/02/2025 and are listed for sale the same date
- No trading-plan date provided: The filing does not state adoption of a Rule 10b5-1 trading plan or instruction date
Insights
TL;DR: Routine insider sale notice; small share amount relative to outstanding stock, disclosed as required.
The filing documents a proposed sale of 8,335 shares via a broker on 09/02/2025 and notes those shares were granted as restricted stock and acquired the same day as compensation. The amounts and values reported are modest versus the 70,373,625 outstanding shares, suggesting limited near-term market impact. Recent past sale on 06/02/2025 of 8,658 shares for $31,470.10 is disclosed, showing prior disposition activity. This is a compliance-driven disclosure under Rule 144 rather than evidence of material company developments.
TL;DR: Filing meets Rule 144 requirements; same-day grant and proposed sale are notable facts to monitor for insider trading policy alignment.
The form confirms the seller represents no undisclosed material information and records compensation-related restricted stock granted and proposed for sale on the grant date. From a governance perspective, the record of grant, prior sale, and broker usage indicates formal reporting compliance. The document does not include a trading plan date or additional context about any 10b5-1 plan, so no conclusions about pre-established instructions can be drawn from this filing alone.